Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Sponsor: Diwakar Davar
Listed as NCT05669846, this PHASE2 trial focuses on Non Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Diwakar Davar, it has been updated 12 times since 2025, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Mar 2025 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Diwakar Davar
- Gateway for Cancer Research
For direct contact, visit the study record on ClinicalTrials.gov .